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Summary
Plain radiograph is the most accepted imaging technique to assess structural changes of osteoarthritis and it is proposed as ‘surrogate’ of
outcome of the disease process. The existing radiographic methodology is well standardized with respect to its technique for investigation
of hip, knee and hand joints, including advice on the most appropriate views, patient positioning, X-ray beam alignment, quality control.
Quantitation of joint space narrowing is currently proposed as the primary variable in studies of disease progression for hip and knee, while
semi-quantitation of this same parameter or of bone changes by published atlases have to be intended as secondary variables, or outcomes
in hand studies. Unfortunately, the review of studies that evaluated the longitudinal rate of joint space narrowing indicates that the yearly
change may be very small (<0.1 mm/year) and of doubtful clinical significance. This underlines the need for further refinement in the
definition of the radiographic outcome in prospective clinical trials.
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Disease outcome measurement in osteoarthritis (OA)
includes different possibilities: (a) ideally, measurement of
the real disease process, that could be obtained only by
pathology assessment; (b) measures of joint pain and
disability, or (c) imaging measurement of joint structural
changes. In the impossibility of performing a pathology
assessment, the remaining two alternatives should be
used. Although clinical measures are probably the best
indicator of the disease and of the activity of a drug, as well
as those most easily appreciated by physicians and
patients, they may be influenced in the long run by different
other factors. Furthermore, the development of severe
disability, i.e., of the disease final outcome, may not be
easy to determine (e.g., the inadequacy of parameters
such as the frequency of joint arthroplasty). Plain radio-
graph is at present the most economical, easily available
and accepted imaging technique to assess structural
changes of OA. It is currently proposed as ‘surrogate’ of
outcome of the disease process, provided that the existing
methodology is sufficiently standardized, but also that it can
reasonably be correlated with symptom change, as cur-
rently required by Regulatory Agencies such as the FDA1
or the EMEA2 and/or the outcome is clinically relevant.Address for correspondence: Lucio C. Rovati, Department of
Clinical Pharmacology, Rotta Research Laboratorium S.p.A., Via
Valosa di Sopra 9, 20052 Monza (MI), Italy.Standardization of the existing methodology
The levels of standardization of the existing radiographic
methodology include the technique, the evaluation vari-
ables and the outcome. Much of the effort during the recent
years has been placed on the standardization of the
technique, in order to limit the sources of variability in
measurement and interpretation, including: patient pos-
itioning, the radiographic procedure (e.g., centering of the427X-ray focal spot, the focus–film distance, etc.), the
measurement process. Different documents have been
produced in this regard, either by scientific bodies such
as the OsteoArthritis Research Society International
(OARSI),3 or the American Academy of Orthopaedic Sur-
geons in conjunction with the WHO,4 or by individual
Authors (e.g.,5,6) and they are concerned with the three
major joints that are today considered the target of investi-
gation, namely the hip, knee and hand. Several basic
aspects are now standard in the radiographic procedure,
such as the use of a fast screen, cassette film and a focus
to film distance of 100 cm. With regard to patient position-
ing, it should be noted that the use of fluoroscopy is
recommended for a correct X-ray beam alignment. Further-
more, hand supports should be provided in some positions
for patient’s stability and foot (or hand) maps may be useful
for repositioning and reproducibility (although even a
multipoint control may be needed in some instances, e.g.,
to avoid body torque about the knee in the weight-bearing
assessment of the hip). For studies involving the hip or the
knee, the current preference goes to weight-bearing
(standing) anteroposterior views of one or both joints.
However, still there may be discussions on the possibility of
accepting hip views with the patient lying on the table and
the feet internally rotated, since the latter appears to apply
a load to the articular surface, possibly obviating the need
for weight-bearing films.4 Similarly, work is still needed to
define if the tibiofemoral compartment of the knee should
be better investigated in the fully extended view or in the
partially flexed view. Conversely, sufficient agreement
exists on the investigation of the patellofemoral compart-
ment of the knee by the skyline (also known as axial, or
sunrise, or sunset) view of each knee and for the dorso-
palmar view of the wrist and hand. Details about patient
positioning and X-ray beam alignment are given else-
where.3,4 Correction for radiographic magnification has
been shown to improve accuracy and precision of
measurements, especially for the hip and knee, since the
distance between the joint and the film may vary among
individuals, or for each individual if significant weight
428 L. C. Rovati: Radiographic assessmentchange occurs between visits.5 Finally, the need for central
reading, quality and reproducibility testing, as well as for
appropriate training of radiologists and technicians, is
acknowledged.studies, it may remain ancillary to clinical outcomes.The evaluation variables
Ideally, global radiographic scales would be a perfect
evaluation variable, since they would consider both
cartilage loss (joint space narrowing) and the bone
response (osteophytes, sclerosis, cysts, etc.) and may be
used for both disease diagnosis (and its staging) and
disease progression (and the grading of this progression).
The Kellgren and Lawrence scale7 has been the first and
most widely used of these attempts. However, the limits
inherent to the scale and to its implementation8 have
favoured the return to the evaluation of individual radio-
graphic features and their separate quantitation, or at least
semi-quantitation. Currently, a prominent feature such as
joint space narrowing (JSN) can be precisely quantitated in
tenths of mm by ruler, calliper and/or a graded magnifying
lens.9 Precision may be improved by digitalization and
computerized techniques of image analysis. Although simi-
lar quantitative methodologies may be applied for bone
response features, semiquantitative grading on a 0–3 scale
has been proposed as a more standardized alternative for
most of them (osteophytes, subchondral sclerosis and
cysts, etc.) and for JSN itself, resulting in the creation of
new atlases that can be easily used for standardization.10
Whatever the selected variable, this should be separately
assessed for each joint compartment.10
Scientific and regulatory agreement apparently exists on
the OARSI3 and GREES11 proposal of using the measure-
ment of JSN at the joint narrowest point as primary variable
in studies of disease progression for hip and knee, while
osteophytes and other bone changes should be regarded
as secondary variables. Conversely, studies of prevention
may better focus on osteophytes, since they are most
strongly associated with pain, at least at the knee, and
they are a basic component of the ACR classification
criteria.12 Radiographic outcomes in studies of the hand
should probably be based on predetermined features
described in published atlases, in the absence of sufficient
standardization of more precise variables.Significance of the radiographic outcome
Published longitudinal studies evaluating the rate of JSN
at the knee joint have been recently reviewed.13 Although
most of these studies are questionable for different
reasons, i.e., the short duration of follow-up for some of
them, or the small number of patients for others, or the
inclusion of patients with different degrees of risk factors for
progression, the rate of JSN varies greatly. Several discus-
sions could by made for the differences in technique and
standardization, but there is a clear indication that the
overall change in JSN may be much less than previously
expected and very small (<0.1 mm/year). Indeed, this has
been recently confirmed by two studies of appropriate size
and duration, one targeted to the investigation of the
natural history of OA in a very selected patient group14 and
the other reporting the results of the placebo arm of a
randomised double-blind trial of a putative Structure
Modifying Drug.15 In both studies the average rate of JSN
was about 0.08 mm/year. The clinical significance of sucha small change is doubtful and indeed the correlation
between radiographic progression and symptom progres-
sion was poor.14 The clear definition of the radiographic
outcome to be pursued in trials of Structure Modifying
Drugs in OA and its validity, is therefore the weak point in
the existing methodology. The view of Regulatory Agencies
may be that until when its standardized clinical significance
is proven in randomized, placebo-controlled, double-blind
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